> Fresh off their successful investigation into device makers' payments to doctors--which led to a total of $310 million in fines and ongoing disclosure agreements--the feds are turning to the other side of the table. Investigators now plan to target doctors for soliciting those kickbacks or bribes. Report [1]

> GlaxoSmithKline told workers at its Ulverston, U.K., plant were told that their jobs were at risk as the company outsources some of their functions; some 330 jobs will be eliminated at the plant, which now employs 537. Report [2]

> Sun Pharmaceutical got the FDA nod for its generic form of Tessalon, a Forest Laboratories cough medicine. Report [3]

> A new survey shows that pharma's medical affairs departments aren't reporting to marketing as much as they did in the past; in 2002, 43 percent of medical affairs units were under the marketing umbrella, but now only 7 percent are. Report [4]

And Finally... Eye on FDA has an interview with former FDA chief David Kessler, who presided over the agency "during much happier times." Report [5]